TSUMURA & CO.
4540・Prime Market・Pharmaceuticals
Governance
As a company with an Audit and Supervisory Committee, the Board of Directors consists of 8 members in total: 3 internal directors and 5 independent outside directors (outside director ratio of 62.5%). From April 2026, the company will introduce an in-house company system, promoting delegation of authority to executive officers and strengthening the Board's supervisory functions.
Risk Management
The Risk Management Committee (convened at least twice a year) works in coordination with the Sustainability Committee to assess and monitor company-wide risks, including climate and natural capital risks, and has established a framework for reporting to the Board of Directors.
Shareholder Returns
DOE is used as the shareholder return indicator, with a target of reaching DOE 5% by FY2031. The annual dividend for FY2026 (ending March 2026) is ¥147 per share (interim ¥68 + year-end ¥79), an increase from ¥136 in the previous fiscal year. For FY2027 (ending March 2027), a dividend of ¥158 (interim ¥79 + year-end ¥79) is planned. Share buybacks were also conducted (¥6,130 million in the current fiscal year).
Dividend Policy
DOE (dividend on equity ratio) is used as the indicator, with dividend enhancement being implemented toward a target of reaching DOE 5% by FY2031. The basic policy is to pay dividends twice a year, an interim dividend and a year-end dividend, with the interim dividend determined by resolution of the Board of Directors and the year-end dividend determined by resolution of the General Meeting of Shareholders. The annual dividend for FY2026 (ending March 2026) is ¥147 per share (interim ¥68 + year-end ¥79), with a payout ratio of 39.4% and DOE of 3.6%. For FY2027 (ending March 2027), a dividend of ¥158 per share (interim ¥79 + year-end ¥79, maintaining the DOE level of 3.6%) is planned. Retained earnings are allocated to growth investments such as capital expenditures and R&D.
ESG
Based on the TCFD and TNFD recommendations, the company integrates management of climate and natural capital risks, and has formulated "Sustainability Targets 2027," which include goals such as a 15% reduction in GHG emissions (Scope 1 and 2) by FY2027 (ending March 2027) and cultivation of 7 wild crude drug items. In terms of human capital, the company has set targets of raising the ratio of female managers to 14.5% by FY2027 (ending March 2027) and achieving a 100% male childcare leave uptake rate, working to promote DE&I and realize a Kampo-like organization.
Last updated: June 23, 2026